1. Home
  2. CRNX vs ESNT Comparison

CRNX vs ESNT Comparison

Compare CRNX & ESNT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Crinetics Pharmaceuticals Inc.

CRNX

Crinetics Pharmaceuticals Inc.

HOLD

Current Price

$35.26

Market Cap

3.9B

Sector

Health Care

ML Signal

HOLD

Logo Essent Group Ltd.

ESNT

Essent Group Ltd.

HOLD

Current Price

$56.91

Market Cap

5.9B

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
CRNX
ESNT
Founded
2008
2008
Country
United States
Bermuda
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Property-Casualty Insurers
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
3.9B
5.9B
IPO Year
2018
2013

Fundamental Metrics

Financial Performance
Metric
CRNX
ESNT
Price
$35.26
$56.91
Analyst Decision
Strong Buy
Buy
Analyst Count
9
7
Target Price
$74.78
$67.86
AVG Volume (30 Days)
903.6K
674.0K
Earning Date
05-07-2026
05-08-2026
Dividend Yield
N/A
2.42%
EPS Growth
N/A
0.73
EPS
N/A
6.90
Revenue
$1,039,000.00
$1,260,935,000.00
Revenue This Year
$722.66
N/A
Revenue Next Year
$183.79
$3.18
P/E Ratio
N/A
$8.40
Revenue Growth
N/A
1.45
52 Week Low
$24.10
$51.61
52 Week High
$57.99
$67.09

Technical Indicators

Market Signals
Indicator
CRNX
ESNT
Relative Strength Index (RSI) 26.12 34.09
Support Level $33.23 $56.84
Resistance Level $37.23 $57.32
Average True Range (ATR) 1.50 1.04
MACD -0.01 -0.06
Stochastic Oscillator 3.41 10.99

Price Performance

Historical Comparison
CRNX
ESNT

About CRNX Crinetics Pharmaceuticals Inc.

Crinetics Pharmaceuticals Inc is a commercial-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its main product, Palsonify (paltusotine), is a once-daily, oral treatment approved by the FDA for adults with acromegaly who have had an inadequate response to surgery and/or for whom surgery is not an option. Additionally, the company's development pipeline includes several programs, including a late-stage investigational candidate, atumelnant, currently in development for CAH and ADCS, and CRN09682, a NDC candidate that is being developed to treat SST2-expressing NETs and other SST2-expressing solid tumors.

About ESNT Essent Group Ltd.

Essent Group Ltd serves the housing finance industry by providing private mortgage insurance, reinsurance, risk management products, title insurance, and settlement services to mortgage lenders, borrowers, and investors to support homeownership. It provides credit protection to lenders and mortgage investors by covering a portion of the unpaid principal balance of a mortgage and certain related expenses in the event of a default. By providing capital to mitigate mortgage credit risk, the company allows lenders to make additional mortgage financing available to prospective homeowners.

Share on Social Networks: